

Report of the statutory auditors to the Board of the foundation

**THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS
(GAFFI)
GENEVA**

APPROBATION DES COMPTES

A retourner à CRF

Lieu et date: Geneva, _____ 2016

Signature:

Financial statements for the year
ended 31 December 2015

_____.2016 HP/ng/3541

Report of the statutory auditors on the limited statutory examination
to the Board of the foundation
THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)

As statutory auditors, we have examined the financial statements (balance sheet, income and expenditure account and notes) of The Global Action Fund for Fungal Infections for the year ended 31 December 2015. The limited statutory examination of the prior year financial statements was performed by another auditor who expressed an unmodified examination conclusion on those financial statements on 8 May 2015.

These financial statements are the responsibility of the Board of foundation. Our responsibility is to perform a limited statutory examination on these financial statements. We confirm that we meet the licensing and independence requirements as stipulated by Swiss law.

We conducted our examination in accordance with the Swiss Standard on the Limited Statutory Examination. This standard requires that we plan and perform a limited statutory examination to identify material misstatements in the financial statements. A limited statutory examination consists primarily of enquiries of foundation personnel and analytical procedures as well as detailed tests of foundation documents as considered necessary in the circumstances. However, the testing of operational processes and the internal control system, as well as inquiries and further testing procedures to detect fraud or other legal violations, are not within the scope of this examination.

Based on our limited statutory examination, nothing has come to our attention that causes us to believe that the financial statements do not comply with Swiss law and the statutes of the foundation.

Geneva, _____ 2016

CRF AUDIT LTD

Hugues Pasquier
Licensed audit expert
Swiss Certified accountant

Enclosures:

- Balance sheet
- Income and expenditure account
- Notes

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)

BALANCE SHEET AS AT 31 DECEMBER 2015

(In Swiss Francs)

	<u>2015</u>	<u>2014</u>
ASSETS:		
<u>Current Asset:</u>		
Bank	204'867	138'808
Prepayments	0	11'626
	<hr/>	<hr/>
TOTAL ASSETS	204'867	150'434
	<hr/>	<hr/>
LIABILITIES:		
<u>Current Liabilities:</u>		
Accounts Payable	8'300	44'047
	<hr/>	<hr/>
TOTAL LIABILITIES	8'300	44'047
	<hr/>	<hr/>
<u>NET ASSETS (Total Assets less Total Liabilities)</u>	196'567	106'387
	<hr/>	<hr/>
<u>Represented by:</u>		
CAPITAL:		
Founding Member's Contribution	50'000	50'000
	<hr/>	<hr/>
TOTAL CAPITAL	50'000	50'000
	<hr/>	<hr/>
GENERAL RESERVES:		
Net Income/(Loss) brought forward	56'387	(23'874)
Net Income for the Year	90'180	80'261
	<hr/>	<hr/>
TOTAL GENERAL RESERVES	146'567	56'387
	<hr/>	<hr/>
<u>TOTAL CAPITAL AND GENERAL RESERVES</u>	196'567	106'387
	<hr/>	<hr/>

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)

INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2015

(In Swiss Francs)

	<u>2015</u>	<u>2014</u>
INCOME		
Bank Interest	0.00	5.10
Contributions (Note 4.i)	275'838.02	199'882.53
	<hr/>	<hr/>
TOTAL INCOME	275'838.02	199'887.63
	<hr/>	<hr/>
LESS EXPENDITURE:		
Launch Expenses	0.00	963.61
Web-design and hosting	0.00	360.82
Travel and meetings (Note 4.ii.a)	19'112.11	3'660.41
Professional fees	1'674.00	2'428.00
Bank Charges	774.40	528.00
Research and Development (Note 4.ii.b)	52'429.36	67'324.54
Consultancy (Note 4.ii.c)	12'003.03	43'060.83
Printing	7'480.39	0.00
Seattle Forum Expenses (Note 4.ii.d)	90'787.38	0.00
Other Expenses	1'397.47	1'300.00
	<hr/>	<hr/>
TOTAL EXPENDITURES	185'658.14	119'626.21
	<hr/>	<hr/>
NET INCOME FOR THE YEAR	90'179.88	80'261.42
	<hr/>	<hr/>

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

1. GENERAL INFORMATION

The Global Action Fund for Fungal Infections (or GAFFI) was created as a Swiss Foundation in July 2013 with the following primary objectives:

- Provision of on-line educational resources for healthcare professionals,
- Estimation of the national burdens of serious fungal infections,
Direct assistance with National Development Plans for Fungal Infection management to attract resources, improve training and facilitate access to diagnostics and appropriate antifungal drugs,
- Building of partnerships with academic (training institutions) and companies, for sustainable improvements in diagnostics, lost-cost antifungal drugs availability and distribution,
- Hosting international meetings to bring key national stakeholders together annually.

The minimum capital of the Foundation was contributed and paid in full by Mrs Carmen Alvarez-Guerra Meneses, founding member and a resident of Geneva, Switzerland.

2. BOARD OF THE FOUNDATION

The Board of the Foundation at the end of the year was constituted of the following members:

Surname	Name	Board	Profession
Denning	David Wemyss	President	Professor of Medicine, University of Manchester and Director, National Aspergillosis Center, Manchester, UK
Rydgren	Victor	Vice-President	Team Leader, Assessio Norge AS, Oslo, Norway
Glauser	Michel Pierre	Member	Past President, Fondation Leenaards and former Chief, Infectious Diseases, University Hospital, Lausanne, Switzerland
Lightfoot	Nigel	Member	Executive Director, Connecting Organizations for Regional Disease Surveillance (CORDS), Lyon, France

During the year, Dr Jorge Alvar Ezquerro resigned for health reasons.

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

During the financial period under review, the Board was supported by Professor David Denning acting as the Acting Executive Director and Mr Rampersad Jugessur, FCCA, as the Deputy Executive Director for Operations and Finance.

3. ACCOUNTING POLICIES

- a. The accounting period is from 01 January to 31 December 2015.
- b. The accounts have been prepared on an accrual basis except for contributions which are recorded on a cash basis.
- c. Expenses relating to the formation of the Foundation have been fully charged to the Income and Expenditure Account in the year they were incurred.

4. INCOME AND EXPENDITURE ACCOUNT

- i. Total income for the year amounted to CHF 275'838. This was made up of contributions received during the year as follows:

Donor	Research & Development	Support for 2015 Seattle Forum
Fondation Jylag	183'407	
Wellcome Trust		15'199
Burroughs Wellcome		7'492
Cidara		4'217
ISHAM		5'000
F2G		7'166
Meridian		5'293
Gilead		15'721
ESCMID		3'003
Healthcare Infection Soc.		4'910
Lumora		4'965
Pulmocide		5'660
Pfizer		13'805
Total	183'407	92'431

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

- ii. Total expenses for the year amounted to CHF 185'658, of which CHF 52'429 (28.3%) was spent on supporting research and development, CHF 90'787 (48.9%) on the Fungal Infections Forum organized and held in Seattle, CHF 12'003 (6.5%) on consultancy and CHF 19'112 (10.3%) on travel. Other expenses were Professional fees (audit) of CHF 1'674 (0.9%), Bank charges of CHF 774 (or 0.4%), Printing of CHF 7'480 (or 4.0%) and other expenses of CHF 1'397 (0.8%).

- a) Travel Expenses were as follows:

Travel to Kenya (DDenning, Jjugessur, JGuto)	11'624.63
Board Meeting Geneva (DDenning, VRydgren)	562.35
Gaffi Awareness Meeting London	2'700.15
Travel to Surinam (DDenning)	2'156.90
Sponsorship of travel of Eduardo Arathoon (Guatemala)	1'259.12
Other travel and meeting expenses	808.96
Total	19'112.11

- b) Research & Development: During the year, CHF 52'429.36 was paid to the University of Manchester for ongoing research and development.
- c) Consultancy: The expenses of CHF 12'003.03 consisted of two payments made to Goodwork Organisation in the UK for artwork, design and printing of GAFFI publications produced in 2015.
- d) Of the total contributions of CHF 92'431 received for the Seattle Forum (Note 4.i), CHF 90'787 were spent as per the table below. They covered the fees of BVGH who helped organized the event; travel of participants from Africa, Asia, Latin America and Europe; meeting expenses which included the cost of hiring meeting rooms and related expenses; and printing of documents, the executive summary and the final road-map. Also included in printing is mailing of the executive summary to every Minister of Health, US senators and other parliamentarians.

Bio Ventures for Global Health	28'319.56
Participants' travel	20'849.15
Meeting Expenses	26'824.01
Printing & Postage	14'794.66
Total	CHF 90'787.38

- iii. The Net Income for the year was CHF 90'180.

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

5. BALANCE SHEET

Assets:

At the end of the year, the bank balance stood at CHF 204'867 and there were no other current or fixed assets.

Liabilities:

Total liabilities amounted to CHF 8'300 and were for the provision of professional fees (2015 Audit).

Net Assets (Assets less Liabilities) were CHF 196'567.

Capital & General Reserves:

The fully paid-in capital remained unchanged at CHF 50'000.

After taking into account the reserve balance of CHF 56'387 brought forward from the previous year, the 2015 Reserves carried forward at the end of the year was CHF 146'567.

The Total Capital and General Reserves were CHF 196'567.

6. OTHER INFORMATION

During the year, GAFFI changed its registered office to a new address at Rue de l'Ancien-Port 14, 1201 Geneva. The office space has been provided free of charge by a Swiss company.

Other benefits in kind received during the year were as follows:

- Board members' and advisers' contribution of their time and skills in attending meetings and providing advice;
- The Fungal Infection Trust (UK) support for maintaining the GAFFI website and news flow;
- The University Hospital of South Manchester for the provision of public relations and communications through ThisisGoodwork organisation.

These benefits in kind have not been reflected in the financial statements.

GAFFI does not own any assets and has not employed any staff during the reporting period.

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

7. FUTURE OUTLOOK

GAFFI continues to pursue its objectives and will be focussed on enabling access to antifungal agents across the world over the coming years. It intends to partner with one or more generic pharmaceutical manufacturers to achieve this objective. Work on the impact of aspergillosis after TB is in the final stages of preparation for publication and this will form the basis of GAFFI's next Global Fungal Infection Forum meeting.

The following activities are ongoing:

- a. A new point of care Fungal Keratitis diagnostic has been initiated in partnership with the University of Manchester, and is funded by a grant from Jylag Foundation. The work has provided enough pilot data for subsequent grant funding.
- b. Direct comparison of the performance of existing commercial assays for *Aspergillus* antibodies for the diagnosis of chronic pulmonary aspergillosis following tuberculosis to ensure adequacy for full international standardisation has been concluded and were published online in 2015.
- c. Efforts are ongoing with the CryptoMag advocacy group and the US agency Supply Chain Management System (SCMS) to improve access to amphotericin B and flucytosine antifungal drugs for fungal meningitis in AIDS.
- d. Applications are ongoing to support national programs in Kenya, Guatemala, China and India. In particular GAFFI has proposed to the government of India that it establishes a Mycology Reference Laboratory in each State. A similar proposal has been floated in China, though senior academics.
- e. Work is ongoing in Uganda on the frequency and clinical impact of fungal complications of Tuberculosis (chronic pulmonary aspergillosis). This will help in the development of the next stage of this area with global implications.
- f. GAFFI added the difficult to treat and disfiguring fungal skin infection chromoblastomycosis to its priority diseases. It has initiated a survey in farmers in Senegal on the frequency of this problem, in association with a foundation based in Paris. GAFFI intends to raise the profile of this disease through its adoption by the World Health Organisation as a neglected tropical disease.
- g. GAFFI's UK partner, the Fungal Infection Trust continues to support the health professional educational program LIFE, with newsletter mailings to ~10,000 health and research professionals.

THE GLOBAL ACTION FUND FOR FUNGAL INFECTIONS (GAFFI)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

- h. In partnership with Bio Ventures for Global Health organisation, GAFFI held a Global Fungal Infection forum in Seattle on 23-24th February 2015. The brought together experts from all continents to focus on reducing deaths from four fungal infections in the developing world: cryptococcal meningitis, histoplasmosis, pneumocystis pneumonia and chronic pulmonary aspergillosis.

The forum led to the issuing of the '95-95 by 2025' 10 year Roadmap. This Roadmap was launched in Melbourne on May 1st and is available on line at www.GAFFI.org/Roadmap. It calls for 95% of the world's population to have access to fungal diagnostics and antifungal treatments by 2025, as well as recommending the set up of Mycology Reference Laboratories in each country and development of 'train the trainers' program for clinicians. The executive summary was mailed to every Minister of Health, to each US Senator and multiple other parliamentarians.